AbbVie Pushes Fed. Circ. To Resurrect Antibody Patent Spat
AbbVie Deutschland GmbH & Co. urged a Federal Circuit panel on Thursday to resurrect two of its antibody patents, alleging that "presumptively prejudicial" jury instructions doomed its infringement suit against a...To view the full article, register now.
Already a subscriber? Click here to view full article